[1]CRIQUI M H,ABOYANS V. Epidemiology of peripheral artery disease[J]. Circul Res,2015,116(9):1509-1526.
[2]MORLEY R L,SHARMA A,HORSCH A D,et al. Peripheral artery disease[J/OL]. BMJ,2018,360:j5842[2022-06-08]. https://doi.org/10.1136/bmj.j5842.
[3]CICERO A F G,SALVETTI M. Peripheral artery disease:a highly prevalent untreated and uncontrolled independent cardiovascular disease[J/OL]. Atherosclerosis,2022,354:55-56[2022-06-08]. https://doi.org/10.1016/j.atherosclerosis.2022.06.1015.
[4]VOLIS I,SALIBA W,JAFFE R,et al. Effect of cerebrovascular and/or peripheral artery disease with or without attainment of lipid goals on long-term outcomes in patients with coronary artery disease[J/OL]. Am J Cardiol,2020,128:28-34[2022-06-08]. https://doi.org/10.1016/j.amjcard.2020.04.043.
[5]BONACA M P,NAULT P,GIUGLIANO R P,et al. Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease:insights from the FOURIER trial(further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk)[J]. Circulation,2018,137(4):338-350.
[6]PARVAR S L,FITRIDGE R,DAWSON J,et al. Medical and lifestyle management of peripheral arterial disease[J]. J Vasc Surg,2018,68(5):1595-1606.
[7]FOWKES F G R,RUDAN D,RUDAN I,et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010:a systematic review and analysis[J]. Lancet,2013,382(9901):1329-1340.
[8]SUNDBØLL J,LARSEN A P,VERES K,et al. Cardiovascular event rates and trajectories of LDL-cholesterol levels and lipid-lowering therapy in patients with atherosclerotic cardiovascular disease:a population-based cohort study[J/OL]. Thromb Res,2019,183:124-130[2022-06-08]. https://doi.org/10.1016/j.thromres.2019.09.034.
[9]ADAY A W,LAWLER P R,COOK N R,et al. Lipoprotein particle profiles,standard lipids,and peripheral artery disease incidence[J]. Circulation,2018,138(21):2330-2341.
[10]RIDKER P M,STAMPFER M J,RIFAI N. Novel risk factors for systemic atherosclerosis:a comparison of C-reactive protein,fibrinogen,homocysteine,lipoprotein(a),and standard cholesterol screening as predictors of peripheral arterial disease[J]. JAMA,2001,285(19):2481-2485.
[11]KENNEDY M,SOLOMON C,MANOLIO T A,et al. Risk factors for declining ankle-brachial index in men and women 65 years or older:the cardiovascular health study[J]. Arch Intern Med,2005,165(16):1896-1902.
[12] ZIERFUSS B,HÖBAUS C,FELDSCHER A,et al. Lipoprotein(a)and long-term outcome in patients with peripheral artery disease undergoing revascularization[J/OL]. Atherosclerosis,2022,363:94-101[2022-06-08]. https://doi.org/10.1016/j.atherosclerosis.2022.10.002.
[13]SMOLDEREN K G,ALABI O,COLLINS T C,et al. Advancing peripheral artery disease quality of care and outcomes through patient-reported health status assessment:a scientific statement from the American Heart Association[J/OL]. Circulation,2022,146(20):e286-e297[2022-06-08]. https://doi.org/10.1161/CIR.0000000000001105.
[14]LIU X M,WANG Y,WU J W,et al. Association between cumulative exposure to increased low-density lipoprotein cholesterol and the new occurrence of peripheral artery disease[J/OL]. Front Neurol,2021,12:696695[2022-06-08]. https://doi.org/10.3389/fneur.2021.696695.
[15]ZHOU Y,LI Y,XU L,et al. Asymptomatic polyvascular abnormalities in community(APAC) study in China:objectives,design and baseline characteristics[J/OL]. PLoS One,2013,8(12):e84685[2022-06-08]. https://doi.org/10.1371/journal.pone.0084685.
[16]WU S L,HUANG Z R,YANG X C,et al. Prevalence of ideal cardiovascular health and its relationship with the 4-year cardiovascular events in a northern Chinese industrial city[J]. Circ Cardiovasc Qual Outcomes,2012,5(4):487-493.
[17]National Cholesterol Education Program(NCEP) Expert Panel on Detection,Evaluation,and Treatment of High Blood Cholesterol in Adults(Adult Treatment Panel Ⅲ). Third report of the National Cholesterol Education Program(NCEP)expert panel on detection,evaluation,and treatment of high blood cholesterol in adults(adult treatment panel Ⅲ) final report[J]. Circulation,2002,106(25):3143-3421.
[18]PRADHAN A D,SHRIVASTAVA S,COOK N R,et al. Symptomatic peripheral arterial disease in women:nontraditional biomarkers of elevated risk[J]. Circulation,2008,117(6):823-831.
[19]BANSAL S,BURING J E,RIFAI N,et al. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women[J]. JAMA,2007,298(3):309-316.
[20]ISO H,NAITO Y,SATO S,et al. Serum triglycerides and risk of coronary heart disease among Japanese men and women[J]. Am J Epidemiol,2001,153(5):490-499.
[21]MORA S,RIFAI N,BURING J E,et al. Fasting compared with nonfasting lipids and apolipoproteins for predicting incident cardiovascular events[J]. Circulation,2008,18(10):993-1001.
[22]NORDESTGAARD B G,BENN M,SCHNOHR P,et al. Nonfasting triglycerides and risk of myocardial infarction,ischemic heart disease,and death in men and women[J]. JAMA,2007,298(3):299-308.
[23]JACOBS D,BLACKBURN H,HIGGINS M,et al. Report of the conference on low blood cholesterol:mortality associations[J]. Circulation,1992,86(3):1046-1060.
[24]FEINGOLD K R,FUNK J L,MOSER A H,et al. Role for circulating lipoproteins in protection from endotoxin toxicity[J]. Infect Immun,1995,63(5):2041-2046.
[25]SAENZ-PIPAON G,MARTINEZ-AGUILAR E,ORBE J,et al. The role of circulating biomarkers in peripheral arterial disease[J/OL]. Int J Mol Sci,2021,22(7):3601[2022-06-08]. https://doi.org/10.3390/ijms22073601.